Trial Profile
Single-Arm, Open-Label, Phase II Trial of Rituximab Plus Sargramostim for the Treatment of Newly Diagnosed Follicular B-Cell Lymphoma in Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 04 Nov 2016 Status changed from active, no longer recruiting to completed.
- 04 Nov 2016 Status changed from active, no longer recruiting to completed.
- 12 Jul 2016 Planned primary completion date changed from 1 May 2017 to 1 May 2018.